Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099 6/01/2026

137,35 USD (+1,00%)

(+1,00%) 6/01/2026

Grafiek Neurocrine Biosciences, Inc.

Grafiek Neurocrine Biosciences, Inc.

1 dag1d 1,00%
1 week1w -3,16%
1 maand1m -11,38%
3 maanden3m 0,26%
6 maanden6m 7,41%
1 jaar1j -0,15%
5 jaar5j 33,58%

Neurocrine Biosciences, Inc. in het nieuws

Toon enkel gratis nieuws

5 januari 2026 · Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

22 december 2025 · Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy · Persbericht

16 december 2025 · Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology · Persbericht

9 december 2025 · Neurocrine Biosciences to Host R&D Day on December 16 · Persbericht

20 november 2025 · Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules · Persbericht

11 november 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences · Persbericht

10 november 2025 · Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder · Persbericht

28 oktober 2025 · Neurocrine Biosciences Reports Third Quarter 2025 Financial Results · Persbericht

17 oktober 2025 · Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules · Persbericht

7 oktober 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results · Persbericht

Profiel Neurocrine Biosciences, Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe